D614G spike mutation
B.1.1.7
1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
4 [4]
5 [5]
6 [6, 7, 8]
1, 2, 3, 9 - Refers to methods and software designed to facilitate the analysis of pathogen genetic sequence data
10 - Korber et al.
11 - ACE2 receptor binding
12 - England using a highly detailed deterministic epidemic model
13 - Increased mortality
14 - Center for Systems Science and Engineering (CSSE) at Johns Hopkins University
10 - Los Alamos COVID-19 Viral Genome Analysis Pipeline
15 - Los Alamos COVID-19 Viral Genome Analysis Pipeline
16 - GISAID
17 - GISAID
18 - cgam package in R 3.6.3
1a: N*mt = WmtNmt = β (1 + s)Np
1b: N*wt = WwtNwt = β Nq
1c: p* = (1 + s)p/(1 + sp)
1d: q* = (1 - p)/(1 + sp)
2a: p(cid:48) = p*(1 - m) + ¯pm
2b: p(cid:48) = p* + (1 - p*)m
3: p(cid:48) = (1 + s)p + (1 - p)m/(1 + sp)
None
90% CrI: [−0.16,0.68]
Fig. 2C
90% CrI: [−0.07,0.60]
Fig. 2F
Fig. 3
Fig. S2
Fig. S3
Fig. S4
Fig. S5
Fig. S6
None
2: Estimated global distribution of selection coefﬁcients for the D614G and B.1.1.7 variants from the population genetics model
10: medRxiv preprint doi: https://doi.org/10.1101/2021.03.29.21254233 
11: medRxiv preprint doi: https://doi.org/10.1101/2021.03.29.21254233 
None
UK: 0.55 (95% CI: [0.50,0.60])
Netherlands: 0.28 (95% CI: [0.20,0.38])
None
25 - simple models
12 - extremely detailed models
36 - methods that allow for more efficient Bayesian inference with stochastic models
89233218CNA000001 - U.S. Department of Energy contract
P01-AI131365 - National Institutes of Health grant
R01-OD011095 - National Institutes of Health grant
R01-AI028433 - National Institutes of Health grant
PHY-2031756 - US National Science Foundation RAPID grant
None
12 - Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (2021).
13 - Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature (2021).
14 - Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases 20, 533–534 (2020).
15 - COVID-19 Viral Genome Analysis Pipeline. https://cov.lanl.gov (2020).
16 - Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob Chall 1, 33–46 (2017).
17 - Global Initiative on Sharing All Inﬂuenza Data. http://www.gisaid.org/ (2008).
18 - Liao, X. & Meyer, M. C. cgam: An r package for the constrained generalized additive
34 Hale, T., Webster, S., Petherick, A., Phillips, T. & Kira, B. Oxford COVID-19 Government Response Tracker (2020).
35 van Dorp, L. et al. No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Nature Communications 11, 5986 (2020).
36 Fintzi, J. et al. Using multiple data streams to estimate and forecast SARS-CoV-2 transmission dynamics, with application to the virus spread in Orange County, California (2020).
37 Mumford, D., Series, C. & Wright, D. Indra’s Pearls: The Vision of Felix Klein. Cambridge University Press (2002).
38 Douc, R. & Cappe, O. Comparison of resampling schemes for particle ﬁltering. In ISPA 2005. Proceedings of the 4th International Symposium on Image and Signal Processing and Analysis, 2005., 64–69 (2005).
B-8: hmax = 1d
B-9: J = 104
B-10: N = 200
None
